AJP - Renal Physiology, Vol 263, Issue 3 546-F553, Copyright © 1992 by American Physiological Society

ARTICLES

Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor

J. Okolicany, G. A. McEnroe, G. Y. Koh, J. A. Lewicki and T. Maack
Department of Physiology, Cornell University Medical College, New York, New York 10021.

A novel small linear C-atrial natriuretic factor receptor ligand [C-ANF-(11-15)] and phosphoramidon (PHO) were used to determine the effects of C-ANF receptor blockade alone, or in combination with inhibition of neutral endopeptidase (NEP), on the pharmacokinetics and metabolism of ANF in the rat. C-ANF-(11-15) infusion decreased apparent volume of distribution (Vss) and metabolic clearance rate (MCR) of administered 125I-ANF-(1-28) to one-third of their control values, whereas PHO alone was without effect on these parameters. In combination with C-ANF-(11-15), however, PHO further decreased MCR of 125I-ANF-(1-28) and increased plasma half time by more than threefold. High-performance liquid chromatography analysis revealed that C-ANF-(11-15) inhibited the delayed appearance of free 125I and [125I]monoiodotyrosine but had no effect on the small proportion of NEP metabolites in plasma. The combination of C-ANF-(11-15) and PHO further delayed the appearance of small metabolites, abolished the appearance of NEP metabolites, and markedly prolonged the permanence of intact 125I-ANF-(1-28) in plasma. The results demonstrate that C-ANF receptor blockade by C-ANF-(11-15) impairs clearance and metabolism of ANF, an effect which is synergistically potentiated by concomitant inhibition of NEP. C-ANF-(11-15) alone or in combination with NEP inhibitors may be a potentially useful therapeutic tool in the treatment of cardiovascular and renal diseases.

This article has been cited by other articles:

				D. M. Dickey, A. R. Yoder, and L. R. Potter A Familial Mutation Renders Atrial Natriuretic Peptide Resistant to Proteolytic Degradation J. Biol. Chem., July 17, 2009; 284(29): 19196 - 19202. [Abstract] [Full Text] [PDF]

				P. S. Andrew and S. Kaufman Guanylyl cyclase mediates ANP-induced vasoconstriction of murine splenic vessels Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1567 - R1571. [Abstract] [Full Text] [PDF]

				R. Almirez and A. A. Protter Clearance of Human Brain Natriuretic Peptide in Rabbits; Effect of the Kidney, the Natriuretic Peptide Clearance Receptor, and Peptidase Activity J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 976 - 980. [Abstract] [Full Text]

				K. Yamada, S. N. Iyer, M. C. Chappell, D. Ganten, and C. M. Ferrario Converting Enzyme Determines Plasma Clearance of Angiotensin-(1–7) Hypertension, September 1, 1998; 32(3): 496 - 502. [Abstract] [Full Text] [PDF]

				T. Omland, A. Aakvaag, V. V. S. Bonarjee, K. Caidahl, R. T. Lie, D. W. T. Nilsen, J. A. Sundsfjord, and K. Dickstein Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction : Comparison With Plasma Atrial Natriuretic Peptide and N-Terminal Proatrial Natriuretic Peptide Circulation, June 1, 1996; 93(11): 1963 - 1969. [Abstract] [Full Text]

				M. A. R. Vieira, M. Gao, L. N. Nikonova, and T. Maack Molecular and Cellular Physiology of the Dissociation of Atrial Natriuretic Peptide from Guanylyl Cyclase A Receptors J. Biol. Chem., September 21, 2001; 276(39): 36438 - 36445. [Abstract] [Full Text] [PDF]